uniQure Inc.: uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington's disease showed the investigative gene therapy was generally well tolerated at this dose with a mean reduction of 53.8% of mutant

Related Keywords

United States ,Amsterdam ,Noord Holland ,Netherlands ,Chiara Russo ,Mariae Cantor ,Matt Kapusta ,Tom Malone ,Committee For Advanced Therapies ,Company Huntington ,European Medicines Agency ,Drug Administration ,Company Lexington ,Wells Fargo ,Advanced Therapies ,Priority Review ,Good Manufacturing Practice ,European Phase ,Data Safety Monitoring Board ,Annual Biopharma Conference ,Global Investment Conference ,Fitzgerald Cell ,Gene Therapy Conference ,Genetic Medicines Summit ,Annual Genetic Medicines Conference ,Conference Call ,Qure Forward Looking ,License Agreement ,Annual Report ,Qure Contacts ,Uniqure ,Nnounces ,Second ,Quarter ,022 ,Financial ,Results ,Highlights ,Ecent ,Company ,Progress ,